Cancer Gene Therapy Market Report 2026

Cancer Gene Therapy Market Overview

• Cancer Gene Therapy market size has reached to $4.21 billion in 2025 • Expected to grow to $8.9 billion in 2030 at a compound annual growth rate (CAGR) of 16.1% • Growth Driver: Rising Cancer Incidence Fueling The Growth Of The Market Due To Increasing Life Expectancy • Market Trend: Breakthrough In Affordable Personalized Cancer Treatment Through Advanced Cell Therapy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cancer Gene Therapy Market?

Cancer gene therapy is a treatment that uses special genes to help fight cancer. It works by changing or adding genes in a person’s cells to stop the cancer from growing. This can help the body attack the cancer more effectively. The goal is to treat the disease in a more targeted and less harmful way than traditional methods. The main types of cancer gene therapies include gene-induced immunotherapy, oncolytic virotherapy, and gene transfer. Gene-induced immunotherapy uses genes to enhance the body's immune system so it can better identify and eliminate cancer cells. It is used for various indications such as large B-cell lymphoma, multiple myeloma, acute lymphoblastic leukemia (ALL), melanoma, and others, and uses different vector types including lentivirus, retrovirus and gamma retrovirus, adeno-associated virus (AAV), modified herpes simplex virus, adenovirus, and others. It is used by several end-users, including hospitals, research institutes, biopharma companies, diagnostic centers, and others.

What Is The Cancer Gene Therapy Market Growth Forecast?

The cancer gene therapy market size is expected to see rapid growth in the next few years. It will grow to $8.9 billion in 2030 at a compound annual growth rate (CAGR) of 16.1%. The growth in the forecast period can be attributed to increasing demand for personalized cancer treatments, rising investment in cell and gene therapy manufacturing, expansion of next-generation viral vectors, growing focus on combination oncology therapies, increasing adoption of precision oncology approaches. Major trends in the forecast period include increasing development of targeted gene therapy platforms, rising adoption of CAR-T and TCR therapies, growing focus on viral vector optimization, expansion of personalized cancer gene treatments, enhanced integration of biomarker-guided therapy selection.

Global Cancer Gene Therapy Market Segmentation

1) By Therapy: Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer 2) By Indication: Large B-Cell Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia (ALL), Melanoma (lesions), Other Indications 3) By Vector Type: Lentivirus, RetroVirus And Gamma RetroVirus, Adeno-Associated Virus (AAV), Modified Herpes Simplex Virus, Adenovirus, Other Vector Types 4) By End-User: Hospitals, Research Institutes, Biopharma Companies, Cell Therapy Manufacturing Centers, Other End Users Subsegments: 1) By Gene Induced Immunotherapy: CAR-T Cell Therapy, TCR (T-Cell Receptor) Therapy, Tumor-Infiltrating Lymphocyte (TIL) Therapy, Dendritic Cell-Based Gene Therapy, NK Cell Gene Therapy 2) By Oncolytic Virotherapy: Adenoviruses, Herpes Simplex Virus (HSV), Reovirus, Vaccinia Virus, Newcastle Disease Virus (NDV) 3) By Gene Transfer: Viral Gene Transfer, Non-Viral Gene Transfer

What Is The Driver Of The Cancer Gene Therapy Market?

The increasing cancer incidence is expected to propel the growth of the cancer gene therapy market going forward. Cancer is a disease characterized by the uncontrolled multiplication of abnormal cells that can invade and spread to other parts of the body, arising in various tissues and organs and classified based on the cell or tissue type from which it originates. Cancer cases are increasing due to rising life expectancy, as the risk of developing cancer grows with age. Cancer gene therapy treats cancer by modifying or replacing faulty genes to stop cancer cell growth or enhance the immune system's ability to destroy them. For instance, in August 2024, Macmillan Cancer Support, a UK-based organization, reported that more than 3 million people in the UK are living with cancer. This figure is projected to increase to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the increasing cancer incidence is driving the growth of the cancer gene therapy industry.

Key Players In The Global Cancer Gene Therapy Market

Major companies operating in the cancer gene therapy market are Bristol Myers Company, Novartis AG, GSK plc., Gilead Sciences Inc., Amgen Inc., Orchard Therapeutics Plc, AGC Biologics, Adaptimmune Limited, Sibiono, Elevate Bio Inc., Bluebird Bio Inc., Uniqure N.V., Shanghai Sunway Biotech Co. Ltd., Anges Inc., Gensight Biologics, Genelux Corporation, Cellectis, Abeona Therapeutics Inc., Kite Pharma Inc., Janssen Biotech Inc., Mustang Bio Inc., Intellia Therapeutics Inc., CRISPR Therapeutics AG, Caribou Biosciences Inc.

Global Cancer Gene Therapy Market Trends and Insights

Major companies operating in the cancer gene therapy market are focusing on developing advanced therapies, such as CAR-T cell therapy, to enhance treatment precision, improve patient outcomes, and target cancer cells more effectively while minimizing damage to healthy tissues. CAR-T therapy is an advanced immunotherapy where a patient’s immune cells are engineered to better detect and destroy cancer cells by adding special receptors to them. For instance, in April 2024, ImmunoACT, an India-based biotechnology company, launched NexCAR19 (actalycabtagene autoleucel), the country's first indigenously developed CAR-T cell therapy for cancer. Specifically designed to treat B-cell lymphomas and leukemias, NexCAR19 works by reprogramming a patient's own T cells to identify and destroy cancer cells. Based on advanced chimeric antigen receptor (CAR) technology, the therapy is locally manufactured, making it more affordable and accessible than imported alternatives. This launch marks a major milestone in India's entry into the global cancer gene therapy space, highlighting significant progress in domestic innovation and personalized cancer treatment.

What Are Latest Mergers And Acquisitions In The Cancer Gene Therapy Market?

In May 2025, AstraZeneca plc, a UK-based biopharmaceutical company, acquired EsoBiotec B.V. for an undisclosed amount. With this acquisition, it aims to strengthen its cell therapy capabilities, accelerating its ambition to develop next-generation treatments in oncology and immune-mediated diseases. EsoBiotec B.V. is a Switzerland-based biotechnology company that specializes in cancer gene therapies.

Regional Outlook

North America was the largest region in the cancer gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cancer Gene Therapy Market?

The cancer gene therapy market consists of revenues earned by entities by providing services such as gene delivery services, clinical trial services, gene editing, and cell-based therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The cancer gene therapy market also includes sales of gene therapy drugs, viral vectors, non-viral delivery systems, and plasmids. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cancer Gene Therapy Market Report 2026?

The cancer gene therapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cancer gene therapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.